Managing diabetes is set to change dramatically by 2026. Endocrinologist reveals 5 cutting-edge technologies that will make care more precise and personalised.
Please provide your email address to receive an email when new articles are posted on . Adults with type 1 diabetes had a higher time in range if they usually administered bolus insulin after a missed ...
CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, Medicaid and other government ...
Alyssa has Type 1 diabetes and has been advised to be on technology called a closed loop system for three months before ...
Ozempic is now available in India as 0.25 mg, 0.5 mg and 1 mg in 'FlexTouch Pen' - an easy-to-use, once-weekly pen device, at a starting cost of Rs 2,200 per week, the company announced here.
For almost two-thirds of his life, Nick Jonas has lived with a chronic condition — type 1 diabetes. The Jonas Brothers-famed ...
Rising Diabetes Drives Technological Advancements in North America Insulin Pen Market: Shift to Self-Care and Home-Based Solutions Spurs Growth. North American Insulin Pen Market North American ...
Researchers warn that spending most of our time indoors could be an overlooked risk factor for metabolic diseases ...
Danish Novo Nordisk launched its blockbuster treatment injection Ozempic in three forms in 0.25 mg, 0.5 mg and 1 mg in the ...
Ozempic is the brand name for a medication called semaglutide, which is primarily used to manage type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists ...
Morning Overview on MSN
A tiny gut-made molecule could rewrite diabetes care
A small molecule made by gut microbes is rapidly emerging as one of the most intriguing new levers for controlling blood ...
Novo Nordisk launched its blockbuster diabetes drug Ozempic, pricing the 0.25 mg dose at $24.35 per week, aiming to capture a vast majority share of the country’s rapidly expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results